It was reported through a research article identifying absorb and xience that may be related to the following; myocardial infarction, device thrombosis, re-hospitalization and final minimal lumen diameter of the scaffold and stent.Additionally, a general statement was made regarding dissatisfaction with absorb.Specific patient information is documented as unknown.Details are listed in the attached article, titled "outcomes of optimised implantation technique with bioresorbable scaffolds: a pooled analysis of absorb-iv and compare-absorb trials".
|
Estimated date.Unique device identifier (udi#): in the absence of a reported part number, the udi cannot be calculated.The device was not returned for evaluation.A review of the lot history record and complaint history could not be conducted because the part and lot numbers were not provided.The investigation was unable to determine a conclusive cause for the reported complaints.The reported potential adverse events of myocardial infarction and thrombosis are listed in the absorb bioresorbable vascular scaffold system, instructions for use as known adverse events associated with the use of a coronary scaffold.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.Additionally, hospitalization appear to be related to circumstances of the procedure.There is no indication of a product quality issue with respects to the design, manufacture, or labeling of the device.
|